Autopsy report · NCT05466747

A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Business decision”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 4
Sponsor: Takeda
Sponsor type: Industry
Conditions: Chronic Obstructive Pulmonary Disease (COPD); Alpha1-Antitrypsin Deficiency
Interventions: RYMPHYSIA; Another Available A1PI
Participants: 0

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.